Abstract
A study published last week in JAMA Network Open by the National Institute on Drug Abuse (NIDA) and the Centers for Disease Control and Prevention (CDC) found that the proportion of opioid overdose deaths involving buprenorphine did not increase in the months after prescribing flexibilities were put in place during the COVID‐19 pandemic. The data provides further evidence that expanding treatment access may help patients, and is consistent with last year's study, also by NIDA and the CDC showing that increased methadone take‐homes did not result in increased methadone overdose deaths.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
